Most lichen sclerosus does not become cancerous. Studies estimate that between 2% and 6% of people with vulvar lichen sclerosus will develop vulvar squamous cell carcinoma over their lifetime, though some research places the risk even lower when patients stick with treatment. The key is knowing which changes are part of the condition itself and which ones signal something more serious that needs a biopsy.
Signs That May Indicate Cancer
Lichen sclerosus on its own causes itching, soreness, white patches, and fragile skin that tears easily. These symptoms, while uncomfortable, are typical of the condition. What you’re watching for are changes that go beyond this baseline, particularly three things: a new lump or raised area, a patch of skin that has become noticeably thicker or harder than the surrounding tissue, or an ulcer or sore that does not heal within four weeks.
A non-healing ulcer is one of the most important warning signs. Skin splitting and small tears are common with lichen sclerosus and usually heal within days. An ulcer that persists for more than four weeks, especially one that looks different from the usual fissures you’re accustomed to, is the kind of change that warrants prompt medical evaluation. Similarly, a firm lump or a patch where the skin texture has shifted from thin and papery to thick, raised, or rough deserves attention. These changes can be subtle, which is why regular self-examination matters.
How Lichen Sclerosus Leads to Cancer
Lichen sclerosus doesn’t jump directly to cancer. The pathway involves chronic inflammation damaging skin cells over time, which can produce a precancerous stage called differentiated vulvar intraepithelial neoplasia (dVIN). This precancerous lesion is the bridge between lichen sclerosus and squamous cell carcinoma. More than half of vulvar squamous cell carcinomas are not related to HPV at all. Instead, they arise from this inflammation-driven pathway linked to conditions like lichen sclerosus.
The precancerous stage can be tricky to spot because dVIN often looks similar to the surrounding lichen sclerosus. It may appear as a slightly raised, thickened, or discolored patch that doesn’t respond to the usual steroid treatment. This is one reason why skin that fails to improve with proper therapy is itself a red flag.
When a Biopsy Is Needed
A biopsy is the only way to definitively rule out cancer or precancerous changes. You can’t tell from appearance alone whether a suspicious area is simply inflamed lichen sclerosus or something worse. A small tissue sample is taken from the concerning area and examined under a microscope.
The situations that typically trigger a biopsy include: a persistent sore or ulcer lasting more than four weeks, a new lump or area of firmness, skin thickening or hardening (sometimes called induration), and skin that does not improve with potent steroid cream treatment. That last point is important. If you’ve been using your prescribed steroid consistently and an area remains unchanged or worsens, the lack of response itself is a reason to investigate further.
The Real Risk by the Numbers
The lifetime cancer risk for people with vulvar lichen sclerosus varies across studies, partly because treatment adherence differs so widely between patient groups. A large Dutch cohort of over 3,000 women found a cumulative cancer incidence of 6.7%. A UK hospital study of nearly 1,000 women reported 3.5%. One Brazilian study found just 0.6% in their patient group, and a striking detail from that research: zero cases of cancer or precancerous changes occurred in patients who were fully adherent to their treatment, compared to 4.7% in those who were not.
A systematic review found the absolute risk could reach as high as roughly 22% in certain populations, but this likely reflects groups with poor follow-up and inconsistent treatment. The pattern across all the data points in the same direction: active, consistent management dramatically lowers risk.
How Treatment Reduces Cancer Risk
Potent topical steroids (typically clobetasol) are the standard treatment for lichen sclerosus, and they do far more than manage symptoms. By controlling the chronic inflammation that drives the condition, consistent steroid use appears to interrupt the pathway from inflamed skin to precancerous changes to cancer.
Research on patients who had already been treated for lichen sclerosus-associated vulvar cancer found that those who used topical steroids afterward had a recurrence rate of 33%, compared to 69% in those who did not use steroids. If steroid treatment can cut recurrence rates in patients who have already had cancer, the protective effect in patients who haven’t yet developed cancer is likely even more meaningful. This makes treatment adherence one of the most powerful tools you have.
Monitoring Between Appointments
Regular self-examination is a practical way to catch changes early. Using a handheld mirror, check the vulvar area monthly for anything new or different. You’re looking for changes relative to your own normal, not comparing to a textbook image. A new bump, a sore that won’t close, a patch that feels firmer or thicker under your fingers, or a change in color that stands out from the usual white patches of lichen sclerosus are all worth reporting.
Clinical guidelines recommend annual follow-up appointments for people with stable, well-managed lichen sclerosus. At these visits, your provider examines the skin and assesses whether treatment is adequately controlling the condition. If you notice any of the warning signs between appointments, don’t wait for the next scheduled visit. A persistent sore, lump, or area of thickening that has been present for more than four weeks should prompt a sooner appointment, as early detection of precancerous changes makes a significant difference in outcomes.
The combination of consistent steroid treatment, self-examination, and regular clinical follow-up is what keeps the cancer risk low. Most people with lichen sclerosus will never develop cancer, and the ones who stay engaged with their treatment and monitoring have the lowest risk of all.